Timing of antiviral treatment initiation is critical to reduce SARS-Cov-2 viral load

Antonio Gonçalves[1], Julie Bertrand[1], Ruian Ke[2], Emmanuelle Comets[1], Xavier de Lamballerie[3], Denis Malvy[4,5], Andrés Pizzorno[6], Olivier Terrier[6], Manuel Rosa Calatrava[6], France Mentré[1], Patrick Smith[7], Alan S Perelson[2] and Jérémie Guedj[1]

[1] Université de Paris, IAME, INSERM, F-75018 Paris, France

[2] Theoretical Biology and Biophysics, Los Alamos National Laboratory, Los Alamos, NM 87545, USA

[3] UMR "Emergence des Pathologies Virales" (EPV: Aix-Marseille University - IRD 190 - Inserm 1207 - EHESP) - Institut Hospitalo-Universitaire Méditerranée Infection, F-13385 Marseille, France

[4] Inserm, UMR 1219, Université de Bordeaux, Bordeaux, France

[5] Centre Hospitalier Universitaire de Bordeaux, Bordeaux, France

[6] CIRI, Centre International de Recherche en Infectiologie, (Team VirPath), Univ Lyon, Inserm, U1111, Université Claude Bernard Lyon 1, CNRS, UMR5308, ENS de Lyon, F-69007, Lyon, France. [7] Certara, Integrated Drug Development, Princeton, NJ, USA

Corresponding author: Jérémie Guedj, jeremie.guedj@inserm.fr

16 rue Henri Huchard, 75018, Paris, France

Conflict of interest

Jérémie Guedj has consulted for F. Hoffman-La Roche. All other authors declared no competing interests for this work.

Ethical statement

Data were originally provided in Young et al. (doi:10.1001/jama.2020.3204) where "waiver

of informed consent for collection of clinical data from infected individuals was granted by

the Ministry of Health, Singapore" and "written informed consent was obtained from study

participants".

Funding statement

Antonio Gonçalves is funded by a grant from Roche Pharmaceutical Research and Early

Development. The study has received financial support of the national research agency (ANR)

through the ANR-Flash calls for COVID-19 (TheraCoV ANR-20-COVI-0018). Portions of

this work were done under the auspices of the U.S. Department of Energy under contract

89233218CNA000001. We also gratefully acknowledge the support of the U.S. Department of

Energy through the LANL/LDRD Program for this work (ASP, RK).

Abstract (word count: 100/200)

We modeled the viral dynamics of 13 untreated patients infected with SARS-CoV-2 to infer

viral growth parameters and predict the effects of antiviral treatments. In order to reduce peak

viral load by more than 2 logs, drug efficacy needs to be greater than 90% if treatment is

administered after symptom onset; an efficacy of 60% could be sufficient if treatment is

initiated before symptom onset. Given their pharmacokinetic/pharmacodynamic properties,

current investigated drugs may be in a range of 6-87% efficacy. They may help control virus

if administered very early, but may not have a major effect in severe patients.

Keywords

SARS-CoV-2; COVID-19; timing for treatment initiation; hydroxychloroquine; interferon-beta-1a; lopinavir/ritonavir; viral dynamics; acute infection; simulations

Main text (word count: 2,503 /4,000)

Background

The outbreak of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which originated in Wuhan, China, has become a global pandemic. By May 7th, 2020, this virus had infected more than 3,700,000 people worldwide and caused more than 260,000 deaths. To readily propose a first line of defense and combat the virus in hospitalized patients, the World Health Organization relies on already existing drugs ("repurposed") that are immediately available in large quantities and have a good safety profile. In coordination with other European institutions, France is implementing a randomized clinical trial in hospitalized patients ("DisCoVery", NCT04315948) comparing the efficacy of lopinavir/ritonavir ± IFN-β-1a, remdesivir and hydroxychloroquine in hospitalized patients. However, the clinical efficacy of currently available therapies is unknown and could be limited [1].

Here we fit mathematical models of viral dynamics to *in vivo* data to estimate parameters driving viral replication. We then use these models to predict the needed efficacy of treatments [2]. By combining the expected drug concentrations and EC_{50} of drug candidates, we also use the model to predict the effects of various dosing regimens (doses, timing of treatment initiation) on viral load dynamics.

Methods

Data used for fitting

We used published data from 13 untreated patients infected with SARS-CoV-2 that were followed in 4 Singapore hospitals [3]. Patients were hospitalized in median at day 3 after onset of symptoms (range: 1-10) and had a median symptomatic period of 12 days (range: 5-24). Viral loads in nasopharyngeal swabs were measured by real time reverse transcriptase polymerase chain reaction (RT PCR, lower limit of quantification: 38 cycles, CT) at multiple time points with an observed peak of viral load at day 5 post onset of symptoms (range: 2-27

days). Data presented in CT were transformed to $\log_{10}$ copies/mL using a published

relationship in Zou et al. [4] and the model was fit to the $\log_{10}$ viral load. Of note, the

transformation from CT to $\log_{10}$ copies/mL does not affect the estimates of parameters of

interest, in particular R_0 and the death rate of productively infected cells. Time since infection

was assumed to be 5 days before the onset of symptoms [5]. In a sensitivity analysis, we also

examined values of 2 and 10 days.

Model

Viral dynamics was fitted using a target cell limited model with an eclipse phase.

$$\frac{dT}{dt} = -\beta VT$$

$$\frac{dI_1}{dt} = \beta VT - kI_1 \qquad\qquad \text{Equation 1}$$

$$\frac{dI_2}{dt} = kI_1 - \delta I_2$$

$$\frac{dV}{dt} = pI - cV - \beta VT$$

The model considers three populations of cells: target cells, T, infected cells in the

eclipse phase, I_1, and productively infected cells, I_2. Given the timescale of the infection, we

neglect target cell proliferation and natural death, and we focused on the process of cell

depletion by virus infection. We assumed target cells become infected with rate constant β.

After an average time of $1/k$, these cells start producing virus and are cleared with per capita

rate δ. Virions are released from productively infected cells I_2 at rate p per cell and are cleared

from the circulation at per capita rate c or lost by infecting a target cell. Based on this model,

the basic reproduction number, R_0, the average number of cells infected by a single infected

cell at the beginning of the infection, is [6,7]

95                 $$R_0 = \frac{p\beta T_0}{\delta(c + \beta T_0)}. \qquad\qquad \text{Equation 2}$$

To determine the target cell concentration, the following calculation was done. We

assumed that the total number of epithelial cells in the upper respiratory tract was 4×10^8

cells, distributed in a volume of 30 mL [8]. Assuming that 1% of these cells express the ACE2

receptor and associated proteases needed for viral entry [9], the target cell concentration, T_0,

was fixed to 1.33×10^5 cells/mL. Following what was found in other viral infections,

including acute infection [6], the clearance rate of virus, c, was assumed to be fast and equal to

10 d^{-1} but values of 5 and 20 d^{-1} were also evaluated.

Model building strategy

Because not all parameters can be identified when only viral load data are available,

parameters V_0 and k were fixed at 10^{-1} copies/mL and 3 d^{-1}, respectively, which corresponds to

an initiation of the viral production 8 hours after cell infection on average [10]. A sensitivity

analysis was also performed with different values of k={1, 3, 5}d^{-1} and V_0={10^{-3}, 10^{-2}, 10^{-1}}

copies/mL to assess the robustness of the parameter estimates. The parameter R_0 was

estimated instead of the infection rate β by a change of variables in Eq. (1).

Parameters were estimated in a non-linear mixed-effect modeling framework using the

SAEM algorithm implemented in Monolix (www.lixoft.com). The model providing the best

description of the data was used for the predictions and the individual data fitting, and model

averaging was used to correct for the model uncertainty when calculating confidence intervals

of estimated parameters [11].

Predicting the effects of treatment according to the antiviral efficacy and the time of

treatment initiation

We assumed that antivirals with a constant effectiveness ε could reduce R_0 by a factor

(1-ε), with ε taking values from 50% to 99% in Equation 2. We considered different times of

treatment initiation, from the time of infection to 3 days after the symptom onset. For each

treatment strategy, we calculated the reduction in viral load at the peak of infection in the

absence of treatment, i.e., 5 days after symptom onset.

Model including an innate immune response

We also examined the possibility that cell infection is limited by an innate immune

response that renders cells refractory to infection, as was proposed for other acute viral

infections [8,12]. In this model, two additional compartments are added, one for a cytokine (eg.,

IFN) released in response to antigen, and one representing cells in an antiviral state that

cannot be infected (Supplemental information).

PK/PD drug properties of lopinavir/ritonavir, hydroxychloroquine, IFN-β-1a and

remdesivir

We relied on the literature to find PK population models and parameter values of

lopinavir/ritonavir [13], plasma hydroxychloroquine [14], IFN-β-1a [15] and remdesivir as well as

reported EC_{50} values *in vitro* (see Table 1). For lopinavir EC_{50}, specific results were obtained

as   follows.   Vero   E6   cells   were   infected   by   SARS-CoV-2   (strain

BetaCoV/France/IDF0571/2020) at a MOI of 0.01 and treated with several concentrations of

lopinavir one hour after infection. Supernatant samples were collected at 48 and 72 hours post

infection. Relative quantification of viral genome was performed by RT-qPCR from RNA

extracted using QIAamp viral RNA Mini Kit (Qiagen). IC50 values of lopinavir (5.246 μM

and 4.941 μM at 48 and 72 hours post infection, respectively) were calculated from dose-

response curve using a four-parameter logistic regression model.

To determine the mean antiviral efficacy of these drugs, we simulated their plasma

pharmacokinetic profiles considering clinical regimens used in the Discovery trial, namely

400/100 mg twice daily (BID) for lopinavir/ritonavir, 400 mg BID the first day (loading dose)

followed by 400 mg once daily (QD) for hydroxychloroquine and 12 MIU for IFN-β-1a. For

each regimen, we simulated N=100 PK profiles according to the reported parameter

distributions. Then, we calculated for each simulated individual the mean inhibitory

coefficient, sometimes called the mean antiviral effectiveness, $\varepsilon = \frac{1}{7} \times \int_0^7 \frac{C(u)}{C(u)+EC_{50}} du$ during

the first week of treatment, and the mean value over the N profiles was given in Table 1. For

comparison purposes, we based the analysis on total plasma concentrations and did not adjust

for plasma protein binding when computing efficacy.

Since the pharmacokinetic parameters of remdesivir have not been reported yet in

humans, the same method could not be applied. We used the summary statistics reported in

the summary for compassionate use of remdesivir filed by Gilead to the EMEA [16] to derive

the mean concentration of the active metabolite in PBMC, C_{mean}, using the AUC after a

loading dose of 200 mg and after repeated doses of 100 mg QD and we assumed that the EC_{50}

for the metabolite was equal to the EC_{50} of the parent [17].

Results

We used a "target-cell limited" model with an eclipse phase [8] given by Eq. (1) to

characterize the viral load dynamics of 13 hospitalized patients in Singapore for which data

obtained from frequent nasopharyngeal swabs were available [3]. Because this model needs to

incorporate a date of infection, an incubation period of 5 days was used as the most plausible

date of infection in each patient [5]. The model fitted the data well (Fig. 1) and using a model

averaging approach to take into account model uncertainty [11], the within-host basic

reproductive number, R_0, was found equal to 8.6 ($CI_{95\%}$ = [1.9-17.6]), and the death rate of

productively infected cells was estimated as 0.60 d^{-1} ($CI_{95\%}$ = [0.22-0.97]), corresponding to a

median half-life of 1.2 days (Table 2 and Fig. S1). In influenza A, another respiratory

infectious disease, estimates of the within host R_0 varied greatly, but the half-life of infected

cells was shorter than 10 hours (see more details in [18]), suggesting a faster clearance of

influenza infected cells than SARS-CoV-2. The viral production rate p was also estimated as

22.7 copies.d^{-1} (CI$_{95\%}$ = [0,59.6]) (Table 2). However, as shown previously, p cannot be

uniquely identified unless the initial target cell density T_0 is known [19,20]. Therefore, the only

quantity that can be reliably estimated is the product p×T_0, equal to 3.0×10^6 copies d^{-1} (CI$_{95\%}$

= [0-7.9×10^6]). Parameter estimates and confidence intervals were also consistent across

models assuming a viral clearance c of 5 or 20 d^{-1} (see Table S1).

Our model along with the parameter estimates given above also inform us both on the

time to initiate antiviral treatment, and the level of efficacy that needs to be achieved to

reduce viral load [6]. As limited information is available on the mechanisms leading to viral

clearance, and how they may be modulated by treatment, we used our model to predict the

effects of treatment at day 5 post symptoms, which corresponds to the time the viral load

tends to peak in the absence of treatment in these data [3]. We considered a simple case where

the drug effectiveness is assumed to be constant after therapy initiation (see methods) and we

calculated the minimal efficacy that would be needed to generate more than 2 logs of viral

decline at peak viral load in the 13 studied patients (Fig. 2). As predicted by viral kinetic

modeling theory [2], we found that the impact of treatment on peak viral load is inversely

correlated with the time of treatment initiation. For a putative treatment blocking the viral

production p and initiated at the time of infection, symptom onset, or 3 days post symptom

onset, a median efficacy of at least 60, 90 and 99% in reducing viral replication would be

needed, respectively, to generate more than 2 log of decline in the peak viral load (Fig. 2).

The results obtained assuming 2 or 10 days of incubation are presented in Fig. S2 and S3. We

also considered the case of a drug like hydroxychloroquine blocking viral infection

(parameter β in Eq. 1). Results were similar to those obtained before as along as the treatment

was initiated before or at symptom onset. However, initiating a treatment 3 days post-

symptoms onset could not reduce peak viral load, regardless of the drug effectiveness (see

Fig. S4).

The model including an innate immune response did not improve the data fitting and

therefore was not selected for inclusion in the main text. However, the same analysis on viral

dynamics and treatment was conducted and the conclusions remained unchanged (see Fig. S5,

S6 and Table S2).

How do these levels of effectiveness compare with the antiviral drugs that are currently

being investigated? To study this question, we assumed that the treatment antiviral

effectiveness at time t after treatment initiation, $\varepsilon(t)$, was related to the plasma total drug

concentration, $C(t)$: $\varepsilon(t) = \frac{C(t)}{C(t)+EC_{50}}$ (except for remdesivir, see methods) and the mean

antiviral effectiveness during the first 7 days of treatment is given by $\bar{\varepsilon} = \frac{1}{N} \times \frac{1}{7} \times$

$\int_0^7 \frac{C(u)}{C(u)+EC_{50}} du$. Given their pharmacokinetic and pharmacodynamic properties (Table 1), we

calculated a mean antiviral effectiveness of up to 66% for lopinavir/ritonavir, 6% for

hydroxychloroquine, 18% for IFN-β-1a and 87% for remdesivir. Given these estimates, these

compounds are unlikely to have a dramatic effect on peak viral load if administered after the

onset of symptoms. In fact, the effective concentrations will presumably be lower in patients,

as drug availability may be further limited by protein binding (in particular for lopinavir,

which has a protein binding rate > 98%) or capability to penetrate respiratory compartments.

Importantly, levels of antiviral efficacy of ~50% could nonetheless be relevant in a

prophylactic setting, before symptom onset, to reduce viral replication in the upper respiratory

tract and reduce the risk of large infiltration to the lung before an effective immune response

is mounted to clear virus [2] Note, above we calculated the effectiveness of drugs administered

in monotherapy for their usual dosing regimen. We did not consider drugs that could directly

target infected cells and lead to their elimination, such as some monoclonal antibodies.

Discussion

Overall our results emphasize that the PK/PD properties of lopinavir/ritonavir,

hydroxychloroquine, IFN-β-1a and remdesivir make them unlikely to have a dramatic impact

on nasopharyngeal viral load kinetics if they are administered after symptom onset. However,

these drugs may be relevant to reduce viral replication if administered early, i.e., as a pre- or

post-exposure prophylaxis. This conclusion however depends on a number of hypotheses that

we discuss below.

First we focused on the capability of drugs to reduce the peak viral load making the

implicit hypothesis that reducing peak viral load would likely reduce symptoms and disease

severity. However the relationship between viral kinetics and disease severity is still debated,

with several studies suggesting that viral load did not differ between patients with severe and

non-severe disease [21,22]. Related to this question, our study had some limitations. Our

calculations relied on blood or plasma drug concentrations. Except for hydroxychloroquine,

for which the ratio of lung to plasma concentration is known to be high[23,24], the lung exposure

of the other drugs that we considered is unknown, and their effect on viral load in the lower

respiratory tract, as measured from broncho-alveolar aspirates for instance, may differ. In

addition, the drug EC_{50} that we used were determined on Vero E6 cells, an *in vitro* system that

may not reflect the *in vivo* EC_{50}. For instance, we found in another study that

hydroxychloroquine had no antiviral activity in a more physiological model of reconstituted

human airway epithelium, and this may explain the absence of antiviral of activity of HCQ *in*

vivo against SARS-CoV-2[24,25]. Finally we focused solely on the antiviral effects of these

drugs, and did not consider other potential effects of these drugs, such as their

immunomodulatory effects. Such effects have been suggested for drugs that are not purely

antivirals, such as hydroxychloroquine and IFN-β-1a[26,27].

Another implicit implication of our work is the benefit of drugs used for prophylaxis,

i.e., before exposure to the virus. In that case the objective of the treatment may be to "flatten

the peak viral load" (by analogy with the now popular terminology of epidemiological

models) but also to prevent infection. Our deterministic, ODE-based model, cannot reproduce

virus extinction, but this can be captured using stochastic version of the same model[28].

Our modeling provides estimates of viral kinetic parameters, in particular R_0 and the loss

rate of infected cells, δ, and the limit of extrapolation of these parameters also need to be well

understood. The advantage of studying this series of patients was the fact that viral load was

sampled extremely frequently and early in the infection. However the number of patients we

studied was quite small (only 13), and the patients were rather young (37 years, range 31-56

years) and may not be representative of patients that are typically evolve to have severe forms

of the disease [21]. Therefore, more data will be needed, from various populations, to estimate

precisely the parameter distribution in the population of patients that are most in need of

antiviral therapy. Finally, our estimate of the loss rate of free virus and infected cells are

constant over time, which neglects the effects of the adaptive immune response. For instance

antibodies, that emerge in the second week after symptom onset[29,30], may contribute to

accelerate viral clearance or reduce viral infectivity. However, to include these effects would

require more complex models and quantitative data on these antibodies and their in vivo

effects, which are currently lacking. Further, our analysis of the antiviral effects of

repurposed drugs focused on their ability to reduce the peak viral load, which typically occurs

well before the antibody response emerges and hence the analysis we presented here should

not be affected in any major way by our neglect of antibody responses.

Future models of drug efficacy may need to account for viral resistance, as it is possible

that continued viral replication in the presence of drug will select for drug resistant mutations

[31], although coronaviruses are unusual in that they appear to have low mutation rates due to

RNA proofreading capability[32]. Drug combination therapy and more aggressive dosing,

including consideration of loading doses to rapidly achieve therapeutic exposures, may be

beneficial to maximize efficacy of these repurposed antiviral agents[33]. For all these reasons,

the outcome of randomized clinical trials remains urgently needed, and the analysis of their

impacts not only on viral clearance but also on disease severity will be critical to design more

potent drugs.

Study highlights (total answers should be less than 150 words)

• What is the current knowledge on the topic?

Repurposed drugs are being evaluated in clinical trials but little is known about their efficacy

on SARS-CoV-2 viral kinetics.

• What question did this study address?

Our study aims to combine PK/PD and viral kinetics modelling to anticipate the effects of

lopinavir/ritonavir, hydroxychloroquine, IFN-β-1a and remdesivir,

• What does this study add to our knowledge?

Given the predicted efficacy of lopinavir/ritonavir, hydroxychloroquine, IFN-β-1a and

remdesivir, it is unlikely that these drugs will have a major effect on viral kinetics if they are

administered as monotherapy after symptom onset.

• How might this change drug discovery, development, and/or therapeutics?

Our results suggest that these drugs should be evaluated in persons exposed to the virus but

prior to appearance of the first symptoms.

Author contributions

AG, RK, ASP and JG designed the research, analyzed viral kinetics data and wrote the

manuscript. JB, EC and PS performed PK/PD predictions ; AP, OT and MRC performed in

vitro experiments. XDL, FM and DM provided guidance on clinical and virological

implications.

References

1. Cao, B. *et al.* A Trial of Lopinavir–Ritonavir in Adults Hospitalized with Severe Covid-

19. *N. Engl. J. Med.* **382**, 1787-1799 (2020).

2. Friberg, L. E. & Guedj, J. Acute bacterial or viral infection—What's the difference? A

perspective from PKPD modellers. *Clin. Microbiol. Infect.* (2019).

doi:10.1016/j.cmi.2019.12.008

3. Young, B. E. *et al.* Epidemiologic Features and Clinical Course of Patients Infected With

SARS-CoV-2 in Singapore. *JAMA* (2020). doi:10.1001/jama.2020.3204

4. Zou, L. *et al.* SARS-CoV-2 Viral Load in Upper Respiratory Specimens of Infected

Patients. *N. Engl. J. Med.* **382**, 1177–1179 (2020).

5. Lauer, S. A. *et al.* The Incubation Period of Coronavirus Disease 2019 (COVID-19) From

Publicly Reported Confirmed Cases: Estimation and Application. *Ann. Intern. Med.*

(2020). doi:10.7326/M20-0504

6. Best, K. *et al.* Zika plasma viral dynamics in nonhuman primates provides insights into

early infection and antiviral strategies. *Proc. Natl. Acad. Sci.* **114**, 8847–8852 (2017).

7. Banerjee, S., Guedj, J., Ribeiro, R. M., Moses, M. & Perelson, A. S. Estimating

biologically relevant parameters under uncertainty for experimental within-host murine

West Nile virus infection. *J. R. Soc. Interface* **13**, (2016).

8. Baccam, P., Beauchemin, C., Macken, C. A., Hayden, F. G. & Perelson, A. S. Kinetics of

influenza A virus infection in humans. *J. Virol.* **80**, 7590–7599 (2006).

9. Muus, C. *et al.* Integrated analyses of single-cell atlases reveal age, gender, and smoking

status associations with cell type-specific expression of mediators of SARS-CoV-2 viral

entry and highlights inflammatory programs in putative target cells. *bioRxiv* (2020).

doi:10.1101/2020.04.19.049254

10. Agostini, M. L. *et al.* Coronavirus Susceptibility to the Antiviral Remdesivir (GS-5734) Is

Mediated by the Viral Polymerase and the Proofreading Exoribonuclease. *mBio* **9**,

(2018).

11. Gonçalves, A., Mentré, F., Lemenuel-Diot, A. & Guedj, J. Model Averaging in Viral

Dynamic Models. *AAPS J.* **22**, 22-48 (2020).

12. Pawelek, K. A. *et al.* Modeling within-host dynamics of influenza virus infection

including immune responses. *PLoS Comput. Biol.* **8**, e1002588 (2012).

13. Wang, K. *et al.* Integrated Population Pharmacokinetic/Viral Dynamic Modelling of

Lopinavir/Ritonavir in HIV-1 Treatment-Naïve Patients. *Clin. Pharmacokinet.* **53**, 361–

371 (2014).

14. Morita, S., Takahashi, T., Yoshida, Y. & Yokota, N. Population Pharmacokinetics of

Hydroxychloroquine in Japanese Patients With Cutaneous or Systemic Lupus

Erythematosus: *Ther. Drug Monit.* **38**, 259–267 (2016).

15. Hu, X. *et al.* COMPARE: Pharmacokinetic profiles of subcutaneous peginterferon beta-1a

and subcutaneous interferon beta-1a over 2 weeks in healthy subjects: Pharmacokinetics

of peginterferon beta-1a and s.c. interferon beta-1a. *Br. J. Clin. Pharmacol.* **82**, 380–388

(2016).

16. Francisco, E. M. EMA provides recommendations on compassionate use of remdesivir for

COVID-19. *Eur. Med. Agency* (2020). <https://www.ema.europa.eu/en/news/ema-

provides-recommendations-compassionate-use-remdesivir-covid-19> Accessed 10 May

2020.

17. Pizzorno, A. *et al. Characterization and treatment of SARS-CoV-2 in nasal and bronchial*

human airway epithelia. (2020). doi:10.1101/2020.03.31.017889

18. Smith, A. M. Host-pathogen kinetics during influenza infection and coinfection: insights

from predictive modeling. *Immunol. Rev.* **285**, 97–112 (2018).

19. Miao, H., Xia, X., Perelson, A. S. & Wu, H. On identifiability of nonlinear ode models

and applications in viral dynamics. *SIAM Rev. Soc. Ind. Appl. Math.* **53**, 3–39 (2011).

20. Stafford, M. A. *et al.* Modeling plasma virus concentration during primary HIV infection.

J. Theor. Biol. **203**, 285–301 (2000).

21. Zheng, S. *et al.* Viral load dynamics and disease severity in patients infected with SARS-

CoV-2 in Zhejiang province, China, January-March 2020: retrospective cohort study.

BMJ **369**, (2020).

22. Liu, S., Zhou, B., Valdes, J. D., Sun, J. & Guo, H. Serum Hepatitis B Virus RNA: A New

Potential Biomarker for Chronic Hepatitis B Virus Infection. *Hepatology* **69**, 1816–1827

(2019).

23. Yao, X. *et al.* In Vitro Antiviral Activity and Projection of Optimized Dosing Design of

Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome

Coronavirus 2 (SARS-CoV-2). *Clin. Infect. Dis.* (2020).doi:10.1093/cid/ciaa237

24. Maisonnasse, P. *et al.* Hydroxychloroquine in the treatment and prophylaxis of SARS-

CoV-2 infection in non- human primates. *Research Square* (2020).doi:10.21203/rs.3.rs-

27223/v1

25. Boulware, D. R. *et al.* A Randomized Trial of Hydroxychloroquine as Postexposure

Prophylaxis for Covid-19. *N. Engl. J. Med.* **0**, null (2020).

26. Liu, J. *et al.* Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in

inhibiting SARS-CoV-2 infection in vitro. *Cell Discov.* **6**, 1–4 (2020).

27. Ingraham, N. E. *et al.* Immunomodulation in COVID-19. *Lancet Respir. Med.*

(2020).doi:10.1016/S2213-2600(20)30226-5

28. Czuppon, P. *et al.* Predicted success of prophylactic antiviral therapy to block or delay

SARS-CoV-2   infection   depends   on   the   targeted   mechanism.

(2020).doi:10.1101/2020.05.07.20092965

29. Woelfel, R. *et al.* Clinical presentation and virological assessment of hospitalized cases of coronavirus disease 2019 in a travel-associated transmission cluster. *medRxiv* (2020).doi:10.1101/2020.03.05.20030502

30. Wu, F. *et al.* Neutralizing antibody responses to SARS-CoV-2 in a COVID-19 recovered patient cohort and their implications. *medRxiv* (2020).doi:10.1101/2020.03.30.20047365

31. Perelson, A. S., Rong, L. & Hayden, F. G. Combination Antiviral Therapy for Influenza: Predictions From Modeling of Human Infections. *J. Infect. Dis.* **205**, 1642–1645 (2012).

32. Denison, M. R., Graham, R. L., Donaldson, E. F., Eckerle, L. D. & Baric, R. S. Coronaviruses. *RNA Biol.* **8**, 270–279 (2011).

33. Smith, P. F., Dodds, M., Bentley, D., Yeo, K. & Rayner, C. Dosing will be a key success factor in repurposing antivirals for COVID 19. *Br. J. Clin. Pharmacol.* (2020).doi:10.1111/bcp.14314

Figure legends

Figure 1: Individual predictions of SARS-CoV-2 of 13 untreated patients from Young et al. [3]

Figure 2: Reduction in viral load at day 5 post symptom onset according to the level of antiviral effectiveness of a treatment blocking the viral production and the timing of treatment initiation (A: at time of infection; B: at time of symptom onset; C: 3days after symptom onset). We assumed an incubation period of 5 days

395 Table 1: PK/PD properties of candidate antiviral drugs. We assume that the total

396 concentrations were the driver of efficacy, and we did not consider intracellular metabolites or

397 free drug concentrations

399 Table 2: Median and confidence intervals of R_0 ,δ and p across models and following model

400 averaging procedure

Table 1.

Drug	PK parameter	EC_{50}	Dosing regimen D0-D7	$\overline{\varepsilon} = \dfrac{1}{N} \times \dfrac{1}{7} \times \displaystyle\int_{0}^{7} \dfrac{C(u)}{C(u) + EC_{50}} du$
Lopinavir/ritonavir	Wang et al. [13]	5.2 μM (unpublished)	400/100 BID	66%
Hydroxychloroquine	Morita et al [14]	4.2 μM [27]	400 mg BID at D0, followed by 400 mg QD	6%
IFN-β-1a	Hu et al. [15]	175 IU/mL [29]	12 MIU at D0, D2, D5	18%
Remdesivir	EMEA guidelines [16]	1 μM [17]	200 mg QD at D0, followed by 100 mg QD	87%

1   **Table 2.**

k (d^{-1})	V$_0$ (log$_{10\ cp/mL}$)	R$_0$ [CI$_{95\%}$]	δ [CI$_{95\%}$] (d^{-1})	p [CI$_{95\%}$] (d^{-1})
1	**10^{-1}**	13.1 [5.1-21.8]	0.68 [0.44-0.9]	26.55 [0-57.32]
	10^{-2}	15.4 [7.9-23.2]	0.71 [0.46-0.94]	32 [8.38-56.26]
	10^{-3}	19.1 [10.3-28.8]	0.71 [0.46-0.94]	35.18 [12.46-60.06]
3	**10^{-1}**	8.2 [3.5-13.1]	0.6 [0.38-0.82]	21.36 [0-60.35]
	10^{-2}	9.8 [4.1-15.4]	0.58 [0.08-1.15]	20.37 [0-85.01]
	10^{-3}	12.5 [4.8-20]	0.58 [0.42-0.74]	23.37 [6.36-39.57]
5	**10^{-1}**	7.1 [0-13.9]	0.6 [0.19-1.06]	22.07 [0-58.57]
	10^{-2}	8.9 [4.7-13.2]	0.57 [0.43-0.74]	22.42 [1.9-41.84]
	10^{-3}	10.2 [4.8-16.2]	0.58 [0.46-0.71]	22.31 [5.48-41.46]
Model averaging		8.6 [1.9-17.6]	0.6 [0.22-0.97]	22.71 [0-59.64]

Time since infection (days)

A If treatment is initiated at day of infection (DI)

B If treatment is initiated at day of symptoms (DS)

C If treatment is initiated at day4 of symptoms (DS+3)